Blood Plasma: Market Shares, Strategies, and Forecasts, Worldwide, 2018 to 2024

 Table of Contents

Abstract: Biotech Serum (Blood) Markets Respond to Healthcare Needs 1
Blood Executive Summary 24
Blood Market Research Executive Summary 24
Blood Market Shares 25

1. Blood: Market Description and Market Dynamics 26
1.1 Blood Plasma 26
1.1.1 Immunotherapy Plus Chemotherapy 26
1.2 Liver Disease Is A Major Cause Of Illness And Death In China 27
1.2.1 Fractionation Technique for Manufacture Blood Products from Plasma: Treatment for Chronic Hepatitis B Infection 29
1.3 Plasma Products Market Trends 30

2. Blood Market Shares and Forecasts 32
2.1 Blood Market Driving Forces 32
2.2 Serum (Blood) Market Shares 34
2.2.1 Blood Serum Providers To China, Market Shares, 36
2.2.2 Blood Company Descriptions 38
2.2.3 Blood Company Descriptions 41
2.2.4 Intense Competition Comes From Local And Overseas Pharmaceutical Enterprises in China 42
2.2.5 30 Approved Manufacturers Of Plasma Products in China 42
2.2.6 Major Competitors in China 43
2.3 Serum (Blood) Market Forecasts 45
2.3.1 Blood Market Segments 46
2.3.2 Transpacific Trade In Human Blood Plasma Products 47
2.3.3 Tons of Blood Plasma 48
2.4 Serum (Blood) Market Segment Forecasts 52
2.4.1 Blood Plasma Protein Treatment Market Segments, Albumin, Polyvalient IVIG/SCIG, Factor X, Factor VIII, Huperimunes 54
2.4.2 IgG 58
2.4.3 Blood Immunoglobulin Segment 60
2.4.4 Blood Market Segment Forecasts, Immunology, Pulmonology, Oncology, Rheumatology, Neurology, Hematology, Transplants and Other Applications 61
2.4.5 Blood Market Segment Forecasts, Disease Treatment, Cell Culture, Medical Device and Scientific Research 63
2.4.6 Blood Market Segment Forecasts, Immunology, Pulmonology, Oncology, Rheumatology, Neurology, Hematology, Transplants and Other Applications 65
2.4.7 Blood Market Is Segmented By Application 67
2.5 Animal and Bovine Serum Market Segments, FBS, ABS, NBCS, BS, Porcine Sera, Dollars, Worldwide, 2017 69
2.5.1 Plasma Proteins Market 70
2.5.2 Plasma Proteins Chinese Market 70
2.5.3 Blood Basic Proteins Market Prospects 78
2.5.4 Global Plasma Supply For Fractionation And The Role of the United States 80
2.5.5 Hep B Treatments 81
2.5.6 Applications For Processed Bovine Serum 81
2.5.7 FBS 84
2.5.8 FBS Cell Culture Process Of Growing Cells Under Controlled Conditions In Vitro 84
2.5.9 ABS 85
2.5.10 Newborn Calf Serum NBCS 86
2.5.11 BCS 86
2.5.12 Porcine Sera 86
2.5.13 Biotechnology Industry 87
2.5.14 Global Animal Health Market 87
2.6 Serum (Blood) Prices 87
2.6.1 Corning Bolvine Serum 88
2.6.2 Millipore / Sigma Aldrich Fetal Bovine Serum, FBS, FCS, Sera, 90
2.6.3 Prices of Pharmaceutical Plasma Products 91
2.7 Serum (Blood) Regional Market 94
2.7.1 US 95
2.7.2 China 96
2.7.3 Chinese Clinical Approval For Human Blood Coagulation Factor VIII 98
2.7.4 Blood Plasma and Serum Providers Improved Fractionation Technologies for China Market, 2017 105
2.7.5 Blood Plasma and Serum Providers Increasing Market Concentration of Top Players China Market, 2017 107
2.7.6 China Mutual Aid Blood Donation 109
2.7.7 China Cord Blood Market For Cord Blood Banking 109
2.7.8 Reimbursement in China 110
2.7.9 Asia-Pacific 111
2.7.10 Europe 111
2.7.11 Australia 111
2.7.12 Company Geographical Revenue 113

3. Serum (Blood) Product Description 114
3.1 Plasma Source of Life 114
3.1.1 Plasma Major Component Of Blood 114
3.1.2 Plasma Carrier For Nutrients, Hormones, Proteins 115
3.2 Plasma Vital To The Regulation Of Body Functions 117
3.2.1 Standardization and Application Of Polymerase Chain Reaction (PCR) 118
3.3 Immunoglobulin Products 119
3.3.1 Subcutaneous immunoglobulin 119
3.3.2 Normal human immunoglobulin 119
3.3.3 Hyperimmune Immunoglobulin Products 120
3.3.4 Hepatitis B Immunoglobulin 120
3.3.5 Treatment for Chronic Hepatitis B Infection 120
3.3.6 Rh(D) immunoglobulin 121
3.3.7 Tetanus Immunoglobulin 121
3.3.8 Zoster Immunoglobulin 121
3.4 Albumin products 122
3.5 Clotting Factor and Other Products 123
3.5.1 Factor VIII 123
3.5.2 Factor IX 123
3.5.3 Factor VIIa 124
3.5.4 FEIBA 124
3.5.5 Prothrombin complex 124
3.5.6 Antithrombin III 125
3.5.7 Protein C 125
3.5.8 Fibrogammin 125
3.5.9 Factor XI and Factor XIII 126
3.5.10 C1 Esterase Inhibitor 126

4. Blood Research and Technology 127
4.1 Bovine Serum 127
4.2 Genetically Engineered Blood Products 128
4.3 Government Regulation 128
4.2.1 United States Government Regulation 129
4.2.2 European Government Regulation 129
4.2.3 Each European Union Member State Has Its Own Procedures for Authorization Of Medicines, Within Its Own Territory, 131
4.3 Cord Blood 131
4.4 Chinese Serum Contaminated with AIDS Virus 133
4.5 Chinese Biological Product Regulations 134
4.6 Chinese Drug Industry Under Attack 134

5 Serum (Blood) Company Profiles 136
5.2 ANZCO Foods / Bovogen Biologicals 136
5.2.1 Clients and Suppliers 137
5.2.2 Development and Prospects 137
5.2.3 ANZCO Foods Jointly Owned by Itoham Foods (Mitsubishi Corporation shareholder), Nippon Suisan Kaisha 138
5.2.4 ANZCO Foods Animal Serum Product Sub-Lots 139
5.2.5 ANZCO Foods / Bovogen Biologicals 139
5.2.6 Bovogen Biologicals 140
5.2.7 ANZCO Foods Revenue 144
5.3 Ausgenex Pty Ltd 144
5.3.1 AusGeneX Revenue 148
5.4 Avantor 149
5.4.1 Avantor / VWR Sole Supplier For Cell And Gene Therapy to Catapult. 149
5.4.2 Avantor / VWR 150
5.4.3 VWR Animal and Human Blood for Use in DNA/RNA Isolation or for Testing Infectious Diseases 151
5.4.4 VWR 151
5.4.5 Avantor Revenue 152
5.4.6 VWR Revenue 152
5.4.7 VMR Plasma-Based Biopharmaceutical Manufacturing Industry in China i 155
5.4.8 VWR Suppliers 155
5.5 Biochrom GmbH 156
5.6 Biotest AG 157
5.7 BPL Group 158
5.8 Cellsera Rutherford 158
5.8.1 Cellsera Rutherford Certificates and Accreditations 160
5.8.2 Cellsera Privately owned, 100% Australian company 162
5.8.3 Cellsera Manufacturing Facility 163
5.9 Changchun SRbiological 165
5.9.1 Zen Bio Human Serum & Animal-Free Growth Supplement 166
5.9.2 Zen Bio Human Serum Technical Advantage Over Animal Serum 168
5.9.3 Zen-Bio Animal Serum - Cell Culture 169
5.10 China Biologic Products 170
5.10.1 China Biologic Sales 171
5.10.2 China Biologic Acquisition TianXinFu 171
5.10.3 China Biologic Products Holdings, Revenue 174
5.10.4 China Biologic Sales Volume Of Products by Segment 175
5.10.5 China Biologic Research And Development Expenses 181
5.10.6 China Biologic Products Holdings, Manufacturing Facilities 184
5.10.7 China Biologic Products Holdings 185
5.11 Chinese Plasma Market and Acquisitions 185
5.11.1 Chinese Blood Product Industry 186
5.11.2 In August 2011, China Shut Down 16 Plasma Stations in Guizhou 190
5.12 Corning Life Sciences 192
5.12.1 Corning Life Sciences Operation 192
5.12.2 Corning Life Sciences Revenue Structure 192
5.12.3 R&D and Investment 193
5.12.4 Corning Life Sciences Sera Products 193
5.12.5 Corning Cell Growth and Differentiation 196
5.12.6 Corning Cancer Research 197
5.12.7 Corning Cell Culture 198
5.12.8 Custom Media and Sterile Solutions 199
5.12.9 Corning® Fetal Bovine Serum 200
5.12.10 Corning Regional Presence 202
CHINA 203
5.13 Global Cord Blood Corp. 208
5.14 CSL 209
5.14.1 CSL 35 Per Cent Annual Growth in Chinese Albumin Sales 209
5.14.2 CSL Bought 80 Per Cent Stake In Chinese Plasma Fractionator Wuhan Zhongyuan Ruide Biologics 209
5.14.3 CSL addresses Market for 100 Million Chinese with Liver Problems 210
5.15 ExCel Bio 214
5.16 GE Healthcare Life Sciences 218
5.16.1 GE HyClone™ Fetal Bovine Serum, Standard 219
5.16.2 GE Healthcare HyClone™ AdvanceSTEM™ ES Qualified Amino Acids 220
5.16.3 GE Healthcare HyClone™ Fetal Bovine Serum (Canada), Characterized 220
5.16.4 GE Healthcare HyClone™ Fetal Bovine Serum, Super Low IgG 221
5.16.5 GE Healthcare HyClone™ Fetal Bovine Serum, Human Mesenchymal Stem Cell Screened 221
5.16.6 GE Healthcare HyClone™ Fetal Bovine Serum (New Zealand), Characterized 222
5.16.7 GE Healthcare HyClone™ Fetal Bovine Serum, Defined 222
5.16.8 GE Healthcare HyClone™ Fetal Bovine Serum, Characterized 223
5.16.9 GE Healthcare HyClone™ Fetal Bovine Serum, Tetracycline Screened 223
5.16.10 GE HyClone™ Bovine Growth Serum 224
5.16.11 CBMG and GE Healthcare Life Sciences China Partner on CAR T-Cell and Stem Cell Manufacturing 225
5.17 Grifols S.A. (GRFS) 225
5.15.1 Grifols U.S. Presence 226
5.15.2 Grifols Revenue 229
5.15.3 Grifols Acquires 24 Plasma Donation Centers in the United States 232
5.15.4 Grifols Plasma Collection 234
5.15.5 Grifols Bioscience Products and Services 235
5.16 Hualan Biological Engineering Inc. 237
5.17 Kedrion S.p.A. 238
5.17.1 Kedrion Revenue 240
5.18 Lake Immunogenics 241
5.18.1 Lake Immunogenics Profile 241
5.18.2 Lake Immunogenics Operation 243
5.19 Lanzhou Minhai 243
5.20 LFB Biotechnologies 244
5.21 Mallinckrodt 244
5.22 Merck KGaA / Millipore / Sigma-Aldrich 245
5.22.1 Sigma-Aldrich Cell Cytotoxicity Assay 247
5.22.2 USA Origin, Sterile-Filtered, Suitable For Cell Culture, Suitable For Hybridoma 249
5.22.3 Merck / BioControl Systems 250
5.23 Moregate Biotech 250
5.24 Newman Biotech 254
5.25 Octopharma AG 254
5.25.1 Octapharma R&D and Investment 255
5.26 Sanpower Group 256
5.27 Selborne Biological Services 256
5.27.1 Selborne Biological Services Animal Blood-Derived Products 260
5.27.2 Selborne Biological Services Plasma 262
5.28 Proliant 264
5.28.1 Proliant Can Produce As Much BSA As The World Uses Each Year 265
5.28.2 Proliant Closed-Loop Processing 266
5.28.3 Lauridsen Group / Proliant 266
5.29 Shanghai RAAS 266
5.29.1 Shanghai RAAS R&D 267
5.29.2 Shanghai RAAS Revenue 267
5.30 Rocky Mountain Biologicals (RMBIO) 267
5.30.1 Rocky Mountain Biologicals Revenue 270
5.31 Sanquin 270
5.32 Takeda / Shire 271
5.32.1 Shire Pharmaceuticals (SHPG) / Baxalta 271
5.32.2 Shire Revenue 272
5.32.3 Shire Hematology 276
5.32.4 Shire Immunology 277
5.32.5 Shire Neuroscience 277
5.32.6 Shire Lysosomal Storage Diseases 277
5.32.7 Shire Gastrointestinal / Endocrine 277
5.32.8 Shire HAE 278
5.32.9 Shire Ophthalmics 278
5.32.10 Shire / Servier Oncology 278
5.32.11 Takeda / Shire Financial Goals 279
5.33 South Pacific Sera 280
5.34 Thermo Fisher Scientific 281
5.34.1 Thermo Fisher Scientific Microbiology 282
5.34.2 Thermo Fisher Scientific Serum Preparation 283
5.34.3 Thermo Fisher Scientific Plasma Preparation 284
5.34.4 Thermo Fisher Animal Serum 286
5.34.5 Thermo Fisher Scientific Quality, Performance, And Consistency Essential To Cell Culture 288
5.35 Beijing Tiantan Biological Products 289
5.35.1 Tiantan Bio Sales Model 292
5.35.2 Tiantan Bio Management Model 293
5.35.3 Tiantan Bio Profile 294
5.35.4 Tiantan Bio Operation 296
5.35.5 Tiantan Bio Revenue Structure 296
5.35.6 Tiantan Bio R&D and Investment 299
5.35.7 Tiantan Bio Development and Prospects 299
5.35.8 Tiantan Biological Products 301
5.35.9 Beijing Tiantan Biological Products Profile 302
5.35.10 Beijing Tiantan Biological Products 303
5.35.11 Tiantan Bio Cosmetic Serum Market 303
5.36 Wuhan Sanli 304
5.37 Wolongsong 305
5.38 ZenBio 305
5.38.1 ZenBio Human Serum 306
5.39 Selected Chinese Blood Companies 308
5.39.1 Global Animal Blood Plasma Products and Derivatives Market 314
5.39.2 Global Bovine Blood Plasma Derivatives Market 314
5.39.3 Blood Serum Industry Key Players. 315
5.39.4 Cosmetic Serum Market 315
5.39.5 Plasma Fractionation Market 315
WinterGreen Research, 316
WinterGreen Research Methodology 317
WinterGreen Research Process 318
Market Research Study 319
WinterGreen Research Global Market Intelligence Company 320

List of Figures

Figure 1. Blood Plasma Market Shares Dollars, Worldwide, 2017 26
Figure 2. Number of Patients with Liver Disease in China and Worldwide 29
Figure 3. US Diagnosis Of Chronic Hepatitis B (CHB). 30
Figure 4. Plasma Proteins Industry Market Growth Factors 31
Figure 5. Blood Market Driving Forces 33
Figure 6. Blood Plasma Market Shares Dollars, Worldwide, 2017 35
Figure 7. Blood Plasma Market Shares, Dollars, Worldwide, 2017 36
Figure 8. Blood Plasma Market Shares Units, Worldwide, 2017 37
Figure 9. Blood Serum Providers To China, Market Shares, Dollars, Worldwide, 2017 38
Figure 10. Blood Plasma Company Descriptions 40
Figure 11. Blood Serum Providers To China, Company Descriptions, Worldwide, 2017 40
Figure 12. Major Plasma Competitors in China 45
Figure 13. Blood Plasma and Serum Providers To China Description, 2017 45
Figure 14. Blood / Plasma / Serum Market Forecasts, Dollars, Worldwide, 2018-2024 47
Figure 15. Blood Market Forecasts, Dollars, Worldwide, 2018-2024 48
Figure 16. Blood Plasma Collection Production, Selected Companies, Tons, Worldwide, 2017 52
Figure 17. Blood Plasma Collection Production, Regional Analysis, Tons, Worldwide, 2017 53
Figure 18. Blood Plasma Market Categories 55
Figure 19. Blood Plasma Proteins Market Segments, Albumin, Polyvalient IVIG/SCIG, Factor X, Factor VIII, Huperimunes, Dollars and Percent, Worldwide, 2017 56
Figure 20. Blood Plasma Proteins Market Segments, Albumin, Polyvalient IVIG/SCIG, Factor X, Factor VIII, Huperimunes, Dollars and Percent, Worldwide, 2012 57
Figure 21. Blood Plasma Proteins Market Forecasts, Dollars, Worldwide, 2018-2024 58
Figure 22. Blood Plasma Protein Treatment Market Segments, Albumin, Polyvalient IVIG/SCIG, Factor X, Factor VIII, Huperimunes, Dollars, Worldwide, 2018-2024 58
Figure 23. Blood Plasma Protein Treatment Market Segments, Albumin, Polyvalient IVIG/SCIG, Factor X, Factor VIII, Huperimunes, Percent, Worldwide, 2018-2024 59
Figure 24. Immunoglobin Blood Market Segment Forecasts, Dollars and Percent Worldwide, 2018-2024 62
Figure 25. Blood Market Segment Forecasts, Immunology, Pulmonology, Oncology, Rheumatology, Neurology, Hematology, Transplants and Other Applications, Forecasts, Dollars, Worldwide, 2018-2024 63
Figure 26. Blood Market Segment Forecasts, Immunology, Pulmonology, Oncology, Rheumatology, Neurology, Hematology, Transplants and Other Applications, Forecasts, Percent, Worldwide, 2018-2024 64
Figure 27. Blood Market Segment Forecasts, Disease Treatment, Cell Culture, Medical Device and Scientific Research, Dollars, Worldwide, 2018-2024 65
Figure 28. Blood Market Segment Forecasts, Cell Culture, Medical Device and Scientific Research. Percent, Worldwide, 2018-2024 66
Figure 29. Blood Market Segment Forecasts, Immunology, Pulmonology, Oncology, Rheumatology, Neurology, Hematology, Transplants and Other Applications, Forecasts, Dollars, Worldwide, 2018-2024 67
Figure 30. Blood Market Segment Forecasts, Immunology, Pulmonology, Oncology, Rheumatology, Neurology, Hematology, Transplants and Other Applications, Forecasts, Percent, Worldwide, 2018-2024 68
Figure 31. Blood Plasma Products In The Food Industry 70
Figure 32. Animal and Bovine Serum Market Segments, FBS, ABS, NBCS, BS, Porcine Sera, Dollars, Worldwide, 2017 71
Figure 33. Blood Market Forces 72
Figure 34. Blood Plasma and Serum Providers To China, Market Shares, Dollars, Worldwide, 2017 73
Figure 35. Blood Plasma and Serum Providers To China Description, 2017 74
Figure 36. Blood Plasma Proteins Market Segments, Albumin, Polyvalient IVIG/SCIG, Factor X, Factor VIII, Huperimunes, Dollars and Percent, Worldwide, 2017 77
Figure 37. Blood Plasma Proteins Market Segments, Albumin, Polyvalient IVIG/SCIG, Factor X, Factor VIII, Huperimunes, Dollars and Percent, Worldwide, 2012 78
Figure 38. Basic Proteins Market Prospects 80
Figure 39. Regulatory Requirements To Establish A Plasma Collection Station In China 84
Figure 40. Safety Features at China’s Plasma Collection Stations: 85
Figure 41. VWR Blood Pricing 90
Figure 42. Corning Life Sciences 92
Figure 43. Millipore / Sigma Aldrich Fetal Bovine Serum, FBS, FCS, Sera, 92
Figure 44. Blood Regional Market Segments, 2017 96
Figure 45. Blood Regional Market Segments, 2017 97
Figure 46. Plasma Collection and Release Volumes in China, 2016 99
Figure 47. Blood Plasma and Serum Providers High Entry BarriersTo China Market, 2017 102
Figure 48. Blood Plasma and Serum Providers High Entry BarriersTo China Market, 2017 103
Figure 49. Blood Plasma and Serum Providers High Entry BarriersTo China Market, 2017 104
Figure 50. Blood Plasma and Serum Providers High Entry BarriersTo China Market, 2017 105
Figure 51. Blood Plasma and Serum Providers High Entry BarriersTo China Market, 2017 105
Figure 52. Comparison of per capita consumptions of selected plasma products in China and the United States in 2015: 106
Figure 53. Blood Plasma and Serum Providers Improved Fractionation Technologies for China Market, 2017 108
Figure 54. Blood Plasma and Serum Increasing Market Concentration Of Top Players To China Market, 2017 109
Figure 55. Chinese Blood Industry Vendor Competitive Strengths 110
Figure 56. Australia Blood Market Metrics 113
Figure 57. Australia Snapshot fo Blood Sector in 2018-2017 114
Figure 58. Thermo Fisher Scientific Revenues, United States, China, Other, Consolidated revenues 115
Figure 59. Plasma Components: 117
Figure 60. Australia Albumin 124
Figure 61. Indications Of Type I And Type Ii Hereditary Angioedema 128
Figure 62. European Centralized Authorization Procedure 132
Figure 63. European Community Compulsory Authorization Procedures: 132
Figure 64. ANZCO Foods Opportunity Created by Bovogen Biologicals Acquisition 138
Figure 65. ANZCO Healthcare Division Value Added By-Products Applications 140
Figure 66. ANZCO Foods Serum Product 141
Figure 67. Bovogen Biologicals Specialty Application Serum Range Features 143
Figure 68. Bovogen Biologicals Specialty Serums 143
Figure 69. Bovogen Biologicals Specialty Products 144
Figure 70. Bovogen Biologicals Partners 144
Figure 71. AusGeneX Plasma Types 146
Figure 72. AusGeneX Quality Serum Products Features 148
Figure 73. AusGeneX Bovine Serum Plasma 149
Figure 74. AusGeneX Purified Proteins 150
Figure 75. AusGeneX Products 151
Figure 76. VWR Product and Customer Groups 2016 154
Figure 77. VWR Plasma Product Portfolio in China 156
Figure 78. Cellsera Foetal Bovine Serum Sterile Filtered 161
Figure 79. Cellsera Rutherford Certificates and Accreditations 162
Figure 80. CellSera Products: 162
Figure 81. CellSera Adult Bovine Serum and Plasma 163
Figure 82. Cellsera State-Of-The-Art Cleanroom Laboratory 166
Figure 83. Cellsera Rooms Monitored By Using Real Time Fixed Particle Counters 167
Figure 84. Zen Bio Fetal Bovine Serum 169
Figure 85. Zen Bio Human Serum Item and Price 170
Figure 86. China Biologic Products Holdings, Regional Locations 175
Figure 87. China Biologic Products Holdings, Regional Locations 175
Figure 88. China Biologic Approved Products, Treatment/Use 180
Figure 89. China Biologic Products Currently in Development Treatment/Use Status of Product Development Stage* 182
Figure 90. China Biologic Product Holdings 185
Figure 91. China Biologic Fully Owned Manufacturing Facilities 186
Figure 92. Chinese Blood Product Industry 189
Figure 93. Blood Plasma and Serum Providers To China, Market Shares, Dollars, Worldwide, 2017 190
Figure 94. Blood Plasma and Serum Providers To China Description, 2017 190
Figure 95. Corning Life Sciences Revenue Structure 194
Figure 96. Corning Life Sciences Sera Products 196
Figure 97. Corning® 100 mL Human AB Serum 196
Figure 98. Corning Human AB Serum 197
Figure 99. Corning Sera in Action 198
Figure 100. Corning Cell Growth and Differentiation 199
Figure 101. Corning Cancer Research 200
Figure 102. Corning Cell Culture 201
Figure 103. Corning® Fetal Bovine Serum 202
Figure 104. Corning FBS Specification Customization 203
Figure 105. Corning FBS Serum Source 203
Figure 106. Corning Regional Products 204
Figure 107. CSL Blood Market Strategy 213
Figure 108. CSL Behring Sales 214
Figure 109. CSL Behring Regional Sales 215
Figure 110. ExCel Bio Fetal Bovine Serum?Standard? 216
Figure 111. ExCel Bio Newborn Calf Serum?Defined? 218
Figure 112. ExCel Bio Newborn Calf Serum?Defined? 219
Figure 113. GE Healthcare Calf Serum 220
Figure 114. GE Healthcare Calf Serum Applications 220
Figure 115. GE Protein Research Animal serum product sub-lots 221
Figure 116. Grifols SA Vertically Integrated Global Plasma Derivatives Target Markets 228
Figure 117. Grifols Plasma Collection 233
Figure 118. Grifols Product Description / Main Applications 238
Figure 119. Kedrion Biopharma Product Brand/Generic Name 241
Figure 120. Lake ImmunogenicsPlasma Antibodies 243
Figure 121. Lake Immunogenics Supplies Vet Schools 244
Figure 122. Moregate Biotech Animal Sera from Australia Or New Zealand 254
Figure 123. Moregate Biotech Animal Proteins Australia Or New Zealand 255
Figure 124. Moregate Biotech Animal Plasma Australia Or New Zealand 255
Figure 125. Moregate Biotech Raw Animal Material for Enzyme Extraction Australian Or New Zealand 255
Figure 126. Octapharma Treatment Of Patients In 113 Countries Across Three Therapeutic Areas 257
Figure 127. Selborne’s Manufacturing Operations General Capabilities 258
Figure 128. Selborne Locations 259
Figure 129. Selborne Facilities 259
Figure 130. Selborne Sourcing 260
Figure 131. Selborne Biological Services product range 261
Figure 132. Selborne Biological Services Sera 263
Figure 133. Selborne Biological Services Plasma 264
Figure 134. Selborne Microbiological Reagents 265
Figure 135. Selborne Sheep and Horse Microbiological Reagents 266
Figure 136. Rocky Mountain Biologicals Single-Source Life Science And Bioprocessing Solutions 270
Figure 137. Rocky Mountain Biologicals Customers 272
Figure 138. Shire Multi-Billion-Dollar Franchises 277
Figure 139. Takeda Cost Synergy Aims 281
Figure 140. Thermo Scientific Divisions 283
Figure 141. Thermo Fisher Scientific Revenues, United States, China, Other, Consolidated revenues 284
Figure 142. Thermo Fisher Scientific Serum and Plasma Tubes 287
Figure 143. Thermo Fisher Animal Serum 288
Figure 144. Thermo Fisher Scientific Sera Product Lines 289
Figure 145. Thermo Fisher Scientific Provides Customized Fetal Bovine Serum (FBS) 290
Figure 146. Thermo Fisher Scientific Customized Fetal Bovine Serum (FBS) Performance FBS 291
Figure 147. Tiantan Biological Has Five Blood Product Production Enterprises in Chengdu Rongsheng, Lanzhou Blood System, Shanghai Blood System, Wuhan Blood System and Guizhou Blood System 293
Figure 148. ZenBio Human Serum 308 

To request a free sample copy of this report, please complete the form below.

Enter captcha code*

We never share your personal data. Privacy policy